A Theoretical Study for Determination of Capoten by Analytical Methods

Rana.S.AL-Shemary[1], Enass Najem Oubaid[2]

[1]Babylon University, College of Pharmacy, Pharmaceutical Chemistry Dept., Hilla, Iraq,
[2]Babylon University, College of Pharmacy, Pharmacology and Toxicology Dept., Hilla, Iraq

Abstract

The present analysis article points out numerous analytical methods for the quantitative identification of ACE inhibitor (ACE Inhibitor) by one in all the spectroscopical techniques (UV-spectrophotometry) and separation techniques, like superior liquid natural action (HPLC). additionally, we tend to examine the contribution of optical biosensors to the clinical and pharmaceutical study of ACE inhibitor, which has applicable analytical procedures for internal control, pharmaceutical drug formulations and human.

In this report, a comprehensive sample of scientific papers published in different journals relating to medicinal, clinical and analytical chemistry was collected. Captopril was chosen because it is a popular medication in the pharmacy, a first-line antihypertensive agent, with a fast release, limited course of operation

Key words :- *Captopril , ACE inhibitor, HPLC, UV, biosensor*

Introduction

Captopril is the first oral angiotensin converting enzyme inhibitor to become available. It was used mainly for hypertension. In mild to severe hypertension, captopril is nearly as effective as normal doses of hydrochlorothiazide or propranolol, nearly one-half of these patients need the use of a diuretic to gain satisfactory regulation of blood pressure. (1)

In extreme hypertension captopril plus a diuretic (and in some cases a beta-blocker) blood pressure has typically lowered considerably better than could be done with 'normal combination treatment' in cases whom have not responded sufficiently to this protocol, and this also resulted in an increased sense of well-being in highly hypertensive patients that have previously undergone comprehensive multiple drug therapy. Indeed, at the present stage of drug production, patients who do not respond to or accommodate 'ordinary' antihypertensive treatment are the most effective candidates for captopril therapy (2).

Ultimately, the final role of captopril in the treatment of hypertension may depend on further confirmation of its profile of adverse effects. Captopril has shown promising changes in a limited number of patients with serious congestive heart failure resistant to traditional treatment, in addition to research on hypertension (3).

Captopril must be considered an interesting addition to the clinical armamentarium; it will continue to create a lot of excitement as its final role in therapy is best described by additional well-designed experiments to evaluate captopril, such as HPLC, UV-visible spectroscopy, GLC, optical biosensor, etc. (4). Captopril tablets are shown in Fig.1.

Figure 1: A picture of captopril tablets.

Discovery and synthesis of captopril

One of the primary medications marketed for lowering blood pressure. Three researchers at the U.S. drug maker Squibb (now Bristol-Myers Squibb) made-up angiotensin converting enzyme inhibitor in 1975: Miguel Ondetti, Claude Bernard Rubin, and David Cushman. In February 1976, Squibb applied for U.S. patent rights for the drug and the U.S. In September 1977, a patent was issued [5]. Captopril's development was one of the early achievements of the groundbreaking idea of ligand-based drug design.

In the mid-20th century, the renin-angiotensin - aldosterone pathway was thoroughly researched and this mechanism provided many important goals in the production of new therapies for hypertension. The first 2 goals that were tried were proteinase associate degreed an angiotensin converting enzyme inhibitor. ACE inhibitor was the results of {attempts|makes associate degree attempt|tries} by Squibb's labs to supply an angiotensin converting enzyme inhibitor. Ondetti, Cushman, and colleagues distended on work undertaken among the 19 Sixties by a team of researchers semiconductor unit by John Vane at the Royal college of Surgeons of European nation. [6]. Kevin K.F. created the first breakthrough. In 1967, the transfer of angiotensin I to angiotensin II was discovered to take place in the pulmonary circulation rather than in the plasma. Sergio Ferreira, on the other hand, noticed that bradykinin dissolved after its transit through the pulmonary circulation. It was believed that angiotensin I to angiotensin II conversion and bradykinin inactivation were regulated by the same enzyme [7].

In 1970, the transfer of angiotensin I to angiotonin was blocked throughout its passage through the circulation mistreatment bradykinin potentiating factor (BPF) equipped by Sergio Ferreira metric Ng and Vane. Later, BPF was found to be a peptide in the lancehead viper venom (Bothrops jararaca),

which was the transforming enzyme's "collected-product inhibitor." A sting from this snake triggers an immediate decrease in its prey's blood pressure, rendering it difficult to run. After it absolutely was found by QSAR-based modification that the terminal sulfhydryl moiety of the amide created a high efficiency of ACE inhibition, Captopril was formed from this peptide.

A non-peptide with a proline residue at the C-terminal is found in the venom. A effective regulator of the so-called angiotensin-converting enzyme (ACE) was found to be this non-peptide. It is a zinc-containing enzyme that catalyzes the synthesis of the angiotensin I peptide into the hormone angiotensin II active peptide that raises blood pressure. While the venom peptide's very quick action can be useful for a starving snake, it is not helpful for humans [8].

Medicinal chemists have produced a sequence of proline-containing zinc-binding compounds using the catalytic mechanism of similar zinc-containing enzymes as the starting point. Succinyl-(S)-proline was the first ACE inhibitor to be synthesized. Medicinal chemists were able to improve the production of the ACE inhibitor more than 1000-fold by replacing the succinyl group with a structurally similar sulfhydryl group. In 1980, Captopril entered the market as the first inhibitor of ACE [9] , as seen in Fig.2.



Figure 2: ACE-inhibitor activity.

It was proprietary in 1976 and approved in 1980 for medicative use. attributable to its mechanism of action and conjointly attributable to the event method, it absolutely was the primary angiotensin converting enzyme inhibitor developed and was thought-about a breakthrough. At E, Captopril was found and grown. Centered on ideas pioneered by Nobel laureate Sir John Vane, R. Squibb & Sons Pharmaceuticals is now sold by Bristol-Myers Squibb.

On April 6, 1981, Captopril received FDA approval. In Feb 1996, once the business exclusivity maintained by Bristol-Myers Squibb for Capoten all

over, the medication became a generic medication within the U.S. The production of Capoten was claimed as an indication of 'biopiracy' (marketing standard medicines), as no benefits flowed back to the associate estral Brazilian community WHO 1st used viper venom as an point poison [10].

Indication

1. Hypertension

Adult /Initially twelve.5-25 mg doubly daily, then augmented to a hundred and fifty mg daily in a pair of separated doses if necessary, doses to be augmented at periods of a minimum of a pair of weeks, once daily dose are often decent if any concomitant medicine medications square measure taken.

Initially 6.25 mg doubly daily, then augmented to a hundred and fifty mg daily if needed in a pair of split doses, doses to be augmented at intervals of a minimum of a pair of weeks, once daily dose are often decent if any concomitant medicine medicines square measure taken.

2- Prophylaxis of symptomatic internal organ failure in clinically healthy patients with symptomless left chamber malfunction (beginning 3-16 days when infarction) following infarction (under close to surgical supervision)

Adult / at first 6.25 mg daily, then hyperbolic to twelve.5 mg three times daily for two days, then hyperbolic to twenty five mg three times daily if tolerated, then hyperbolic to 75-150 mg daily if tolerated in 2-3 separated doses, rising steady to doses larger than seventy five mg daily.

3-Diabetic nephropathy in type 1 DM

Adult/75-100 mg in split doses daily.

4-Heart failure

Adult/(under shut medical supervision) at first 6.25-12.5 mg 2-3 times every day, then hyperbolic more and more at periods of a minimum of a pair of weeks, if tolerated up to a hundred and fifty mg daily in divided doses.

5-Short-term treatment of clinically competent patients with myocardial infarction within 24 hours of onset.

Captopril analytical measurement

Several assay strategies, like coulometric [13] , conductometric, and colorimetrical, are developed for the quantitative determination of Capoten [14]. Infrared spectroscopy [15], mass spectroscopy and nuclear magnetic resonance spectroscopy [16] are used to determine Captopril. Captopril's UV spectrum with one band at two hundred nm was obtained, whereas the CD spectrum consists of one peak at 210 nm [17].

Captopril by spectrophotometric method was calculated by Alberto [18] and iron and copper complexation with ACE inhibitor was additionally assayed [19] by ultraviolet illumination photometer. the amount of chromatographical strategies for the determination of ACE inhibitor has been defined as gas chromatography-mass spectrometry [20] Ahmed et al. [21] also published HPLC stability-indicating methods for its determination.

This approach is employed for the assessment of angiotensin converting enzyme inhibitor in pure type within the presence of the disulphide chemical compound and in pharmaceutical preparations, an answer containing 0.025 C and w / w Pd(II) chloride was used as a mobile step in a very mixture of acetonitrilemethanol-water comprising ten millimetre Britton-Robinson [BRb] pH scale 4.00 and 0.25 M KCl solution [1:4:5 v / v / v].

Another HPLC methodology determined by Stulzer et al. angiotensin converting enzyme inhibitor in controlled unleash tablets and analyzes

were performed at temperature at the inverted part Phenomenex Luna column C18 (250 millimetre × 4.6 mm), mobile part water: methyl alcohol (45:55; v / v) and pH scale 2.5 at 1.0 mL.min^{-1}, and also the response was linear at zero.3–1.5 mg.mL^{-1} (r^2 = 0.9983) [22].

Ivanovic et al. have revealed a valid RP-HPLC method for analyzing hydrochlorothiazide and Capoten in tablets. Jankowski et al., calculated by HPLC in blood with captopril [23]. The captopril adduct recovery achieved 93.1% and the detection limit was 15 ng.mL^{-1}, while the conceptual limit was 30 ng.mL^{-1}. Inter and intra-assay RSD were below 9%, but precision was found to be below 8%. Captopril was calculated by Saleem et al. and Amini et al. [24]in plasma.

For the quantitative determination of angiotensin converting enzyme inhibitor by the quantity of scientists victimisation HPLC [25], variety of assay strategies are developed. a range of examinations are recorded victimisation HPLC for the determination of angiotensin converting enzyme inhibitor in bulk drug substances and their formulations [26]. Direct determination of the four ACE-inhibitors Zestril, Enalapril, angiotensin converting enzyme inhibitor and Fosinopril in prescription drugs and blood serum by HPLC analyst separation was accomplished by RP-HPLC gradient with a mobile step consisting of acetonitrile: water (60:40 v / v) with ortho oxyacid changed to pH 3.0 [26] , Fig.3 demonstrates captopril's chemical composition.



Figure 3: captopril's chemical structure.

Monitoring of in vitro trials of ACE inhibitor association with LC-UV symptom agents and parallel LC determination of rosuvastatin, lisinopril, captopril, and angiotensin converting enzyme inhibitor in API, medicament formulations, and human blood serum [27]

Another Facile and Manifest Liquid chromatographical method for coinciding Determination of ACE inhibitor and NSAIDs in API and Pharmaceutical Formulations has been according and CAP has been isolated from NSAIDs by means that of a column of Purospher STAR C18 (250.4.6 mm, five μm) and a mobile section consisting of alcohol, water (80:20,v / v)[28].

Therefore, ACE inhibitor with water pill HydroDIURIL and diuretic in active pharmaceutical ingredients, medicative indefinite quantity formulations and human body fluid area unit used as combination indefinite quantity forms for alternative distinctive forms of drug substances like metal channel block medicinal drug, diuretics, etc. [29].

Other hypoglycaemic Capoten, medicinal drug and H2 receptor antagonist ways ar recorded in bulk, formulations, and human humor by RP-HPLC [30-32].

Biosensors have become important bioanalytical instruments in the last few years for environmental testing, biotechnology, pharmaceuticals, food safety and other consumer industries. Due to their high sensitivity, high precision, low expense, compact size and simple activity, the use of biosensors to test chemical species is an exciting opportunity.

High sensitivity and fast detection are key criteria for a sensor for detecting biomaterials. There has been a great deal of study over many decades to develop quick and responsive biosensors for various applications. In particular, owing to the probability of fast and direct (unlabelled) detection, optical methods have been reported to have a high potential.

A variety of biosensor instruments, including several interferometers, surface plasmon resonance sensors and micro ring resonator sensors, have been used to detect various biomaterials. While all these sensors offer sensitive and quick detection, they are only suitable for items up to 100 nm in size [33].

A light detector resistance (LDR) is AN optical device mounted in an exceedingly black PTFE cell and paired to a cheap multimeter (Ohmmeter). The chemical analysis is based on the reduction of ammonium ion molybdate by Capoten, producing a green-yellow compound in the presence of sulphuric acid (λmax 407 nm). By plotting the electrical resistance of the LDR against the CPT concentration, the standardization curves were obtained within the vary of 4.60×10^{-4} to 1.84×10^{-3} $mol.L^{-1}$ with an affordable constant of determination ($r^2 = 0.9962$) [34].

Moreover, as a result of their uncommon optical properties and catalytic ability, Molybdenum compound nanomaterials have recently attracted widespread interest. There is, however, no literature up to now on the utilization of photoluminescent nanomaterials of Molybdenum compound in biological and pharmaceutical sensing.

Via Associate in Nursing easy method, photoluminescent Molybdenum oxide compound quantum dots (MoOx QDs) were synthesized and so the synthesized MoOx QDs were more additional as a replacement sort of photoluminescent probe to create a replacement off-on angiotensin converting enzyme inhibitor (Cap) detector supported the idea that the quenched photoluminescence of MoOx QDs by Cu^{2+} was fixed up to Cap by precise interaction between thiol cluster of Cap and Cu^{2+}.

The rebuilt photoluminescence strength showed a powerful linear relationship with the Cap material, variable from 1.0 to 150.0 μM, with a 0.51 μM (3σ / k) detection most, beneath ideal conditions. additionally,

with the recently designed off-on device, the content of Cap was with success known in pharmaceutical samples, and therefore the recoveries were 99.4-101.7 percent, indicating that the newest off-on device includes a high accuracy.

Replicate (n = 10) measurements were created on an equivalent answer comprising the equivalent of 1.15 x 10^{-3} mol.L^{-1} of CPT to check the repeatability and preciseness of the measure methodology. Determinations (n = 10) were created with an equivalent answer containing CPT adequate to 1.15 x 10^{-3} mol. L^{-1}.

This resolution was tested in conjunction with the prescribed approach for measurement the CPT content of pharmaceutical formulations. In terms of share relative variance (% RSD) [36], the accuracy was measured.

The Biosensors Specifications

The essential specifications for biosensors are the following:

Ø Ability to provide real-time data during a project at each development stage or at multiple time points. This would help in improved tracking and regulation of blood sugar levels, for example.

Ø It is feasible to customise several biosensor technologies to permit continuous flow analysis that's terribly helpful in food process, observance of installation, and air quality.

Ø Through miniaturization, biosensors can reduce usage costs and can be incorporated into efficient, highly capable lab-on-a-chip tools.

Ø Biosensors is used for point-of - care or on-the-spot analysis wherever progressive molecular analysis is conducted while not the requirement for a progressive laboratory [37].

Biosensor system

In general, a biosensor uses a facet of biological recognition that detects the presence of an analyte (the species to be detected) and produces a physical or chemical change that's remodeled into a symptom by an electrical device (detector). The general block diagram of the framework of biosensors is defined in Fig. 4. Specific system for biosensing. An analyte is inserted into the detector by the sampling machine. The identification issue attaches or responds to a specific analyte, giving a biodetection specificity. Enzymes, antibodies, proteins, DNA or additionally cells like yeast or bacterium are used as parts in biorecognition [38]. In general, stimulus may be generated by optical, electrical, or other kinds of force fields that, as a result of biorecognition, extract a reaction. The transduction mechanism converts the physical or chemical process of biorecognition into an optical, electrical or another variety of signal within the presence of external stimuli that's then detected by the detector device. For identification of the analyte, the detection device may provide pattern recognition.

A broad variety of real life applications are defined by biosensors [39]. In essence, future uses are medicinal and nonclinical [40]. The use of biosensors to track toxins [41], micro-organisms, microbes, viruses [42] and chemical and biological defense against terrorism is of more recent concern. In agricultural and environmental applications [43], it is also common. A few days now, applications based on nanotechnology [44] are also being created.



Figure 4: General Scheme of biosensing.

The Immobilization Techniques (Mechanism)

The biological part has to be correctly attached to the transducer to make a biosensor. Immobilization is called this method. On a solid support, the biorecognition components are typically immobilized. A membrane, rubber, copolymer, or semiconductor material are typically the solid supports. A biorecognition component, either by a physical methodology (such as adsorption) or by chemical association, is immobilized on the solid support. In sure ways, the issue of biorecognition is cursed with controlled porousness within the volume of the matrix (solid support), wherever solid support typically provides property against associate analyte of a precise size in step with its pore dimension [44].

Conclusion

A significant variety of drugs for effective treatment are administered to people diagnosed with hypertension, raising the risk of adverse effects and drug reactions. But Gupta et al. [37-44] have documented some electro analytical approaches.

UV and HPLC strategies and optical biosensors for the determination of ACE inhibitor in active ingredients, pharmaceutical formulations and biological specimens square measure investigated alone or in conjunction with different medication during this study.

In general, pricey instrumentation, provision for the utilization and disposal of solvents, labour-intensive sample preparation procedure and private skilled chromatographical techniques were needed for HPLC strategies.

Furthermore, several of the examined HPLC approaches have the ability to apply drug combination, multi-drug pharmacokinetics trials and association studies to clinical science.

Thus, optical biosensors are one of the most interesting alternatives in this situation, since they play an important role in drug quantification and are one of the most specific, sensitive, low-cost and

easy-to-use options available at the moment. This has provided a niche for them as new clinical instruments that allow more precision medicine to be controlled therapeutically by minimizing symptoms or secondary effects as much as possible and contributing to safer patient treatment and prescription.

In addition, the use of biosensors offers doctors a benefit when making the most precise choices for real-time dosing at the bedside of a patient, since biosensors are compact instruments that are easy to use and miniaturized. When formulating medicines, they have stricter and more effective regulation. There is an immediate need for more research based on the quantification of blood medications and including all pharmacological classes to ensure that a greater range of medications have personalized doses in accordance with the premise of usage.

Funding : The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest there has been no conflict of interest of any kind with the authors of this work

Ethical standard: The study was formally approved the research plan by the ethical committee board at the Babylon health directorate.

Informed consent was taken from all the participant patients before being enrolled in the study

References

1. Harrison DA, Mohammed S, McGrath JE, Florey AT, Vander-stoep SW. Time matters in team performance: Effects of member familiarity, entrainment, and task discontinuity on speed and quality. Personnel Psychology. 2003 Sep;56(3):633-69.
2. Eder HA. The pharmacological basis of therapeutics. by LS Goodman and A. Gilman, Macmillan, New York. 1975:744.
3. Guerrero RS, Vives SS, Calatayud JM. Fluorimetric determination of captopril by flow injection analysis. Microchemical journal. 1991 Jun 1;43(3):176-80.
4- Zhang XR, Baeyens WR, Van der Weken G, Calokerinos AC, Nakashima K. Chemiluminescence determination of captopril based on a Rhodamine B sensitized cerium (IV) method. Analytica chimica acta. 1995 Feb 28;303(1):121-5.
5. Goodman LS. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 1996.
6. FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. The Journal of nutrition. 2004 Apr;134(4):980S-8S.
7. Cushman DW, Ondetti MA, Gordon EM, Natarajan S, Karanewsky DS, Krapcho J, Petrillo Jr EW. Rational design and biochemical utility of specific inhibitors of angiotensin-converting enzyme. Journal of cardiovascular pharmacology. 1987 Jan 1;10:S17-30.
8. Goldnik A, Gajewska M, Ostaszewska B. Measurement of Some Antidepressants in Body Fluids by High Performance Liquid Chromatography. Acta poloniae pharmaceutica. 1991;48(3-4):5-7.
9. El-Kerdawy MM. Moustafa. Mohamed A., El-Ashry, Saadia M., El-Waseef, Dalia R. J. Pharm. Sci.;9(2):191-203.
10. Atzei D, Rossi A, Sadun C. Synthesis and characterization of a cobalt (III) complex with 1-(D-3-mercapto-2-methylpropionyl)-L-proline. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2000 Sep 1;56(10):1875-86.
11. Atzei D, Sadun C, Pandolfi L. X-ray photoelectron spectra of complexes with 1-(d-3-mercapto-2-methylpropionyl)-l-proline and Ni (II), Cd (II) and Cu (I): synthesis and LAXS study of Cu (I) derivative. Spectrochimica Acta Part A: Molecular

and Biomolecular Spectroscopy. 2000 Feb 15;56(3):531-40.

12. Casy AF, Dewar GH. Captopril and its probable contaminants: NMR and MS features of analytical value. Journal of pharmaceutical and biomedical analysis. 1994 Jul 1;12(7):855-61
13. Brittain HG, Kadin H. Ultraviolet (UV) absorption and circular dichroism (CD) spectra of captopril. Pharmaceutical research. 1990 Oct;7(10):1082-5.
14. Albero MI, Sánchez-Petreño C, Garciá MS, Ródenas V. Determination of captopril in pharmaceutical samples by flow injection analysis. Journal of pharmaceutical and biomedical analysis. 1993 Oct 1;11(10):887-91.
15. Fernandez MT, Silva MM, Mira L, Florêncio MH, Gill A, Jennings KR. Iron and copper complexation by angiotensin-converting enzyme inhibitors. A study by ultraviolet spectroscopy and electrospray mass spectrometry. Journal of inorganic biochemistry. 1998 Aug 1;71(1-2):93-8.
16. Franklin ME, Addison RS, Baker PV, Hooper WD. Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography–mass spectrometry and its application to pharmacokinetic studies. Journal of Chromatography B: Biomedical Sciences and Applications. 1998 Jan 23;705(1):47-54.
17. Ahmed S, Rizk M, Belal F, Ibrahim F, Sheribah ZA. Stability-Indicating HPLC Method for Captopril Through Pre-Column Derivatization with Pd (II). Journal of liquid chromatography & related technologies. 2006 Feb 1;29(4):521-32.
18. Stulzer HK, Tagliari MP, Kuminek G, Oliveira PR, Bertol CD, Silva MA. Development and validation of stability indicating LC method to quantify captopril in tablets of controlled release. Chromatographia. 2009 Jun;69(2):123-8..
19. Ivanovic D, Medenica M, Malenovic A, Jancic B. Validation of the RP–HPLC method for analysis of hydrochlorothiazide and captopril in tablets. Accreditation and quality assurance. 2004 Jan;9(1):76-81.
20. Jankowski A, Skorek A, Krzyśko K, Zarzycki PK, Ochocka RJ, Lamparczyk H. Captopril: Determination in blood and pharmacokinetics after single oral dose. Journal of pharmaceutical and biomedical analysis. 1995 Apr 1;13(4-5):655-60.
21. Salem II, Saif WA, Jmeian Y, Al Tamimi JI. A selective and rapid method for the quantification of captopril in human plasma using liquid chromatography/selected reaction monitoring mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2005 Apr 29;37(5):1073-80.
22. Amini M, Zarghi A, Vatanpour H. Sensitive high-performance liquid chromatographic method for determination of captopril in plasma. Pharmaceutica Acta Helvetiae. 1999 Jun 1;73(6):303-6.
23. Du M. Determination of captopril in human plasma by liquid chromatography/tandem mass spectrometry. Analytical letters. 2007 Dec 1;40(17):3245-55.
24. Huang T, He Z, Yang B, Shao L, Zheng X, Duan G. Simultaneous determination of captopril and hydrochlorothiazide in human plasma by reverse-phase HPLC from linear gradient elution. Journal of Pharmaceutical and Biomedical Analysis. 2006 May 3;41(2):644-8.
25. Alnajjar AO. Simultaneous CE determination of captopril and indapamide in pharmaceuticals and human plasma. Chromatographia. 2008 Sep;68(5):437-42.
26. Pérez-Ruiz T, Martínez-Lozano C, Galera R. Development and validation of a capillary electrophoresis method with laser-induced fluorescence detection for the determination of captopril in human urine and pharmaceutical preparations. Electrophoresis. 2006 Jun;27(12):2310-6.

27. Naveed S, Sultana N, Arayne MS. Method for the Determination of Captopril in Bulk, Pharmaceutical Formulations and Serum by HPLC using two different System. American Based Research Journal. 2013;2.

28. Sultana N, Naveed S, Arayne MS. Direct determination of four ACE-inhibitors lisinopril, enalapril, captopril and fosinopril in pharmaceuticals and serum by HPLC. J Chromat Separation Techniq. 2013;4(179.5):1-5.

29. Sultana N, Naveed S, Arayne MS. Development and validation of a simple and efficient RPLC method for analysis of captopril, metformin, pioglitazone and glibenclamide in API, formulations and human serum. Pharm Anal Acta. 2013;4(257):2.

30. Arayne MS, Sultana N, Tabassum A, Ali SN, Naveed S. Simultaneous LC determination of rosuvastatin, lisinopril, captopril, and enalapril in API, pharmaceutical dosage formulations, and human serum. Medicinal Chemistry Research. 2012 Dec;21(12):4542-8..

31. Sultana N, Arayne MS, Naveed S. Simultaneous Quantitation of Captopril and NSAID's in API, Dosage Formulations and Human Serum by RP-HPLC. Journal of the Chinese Chemical Society. 2010 Feb;57(1):62-7.

32. Sultana N, Arayne MS, Naveed S. RP-HPLC method for simultaneous determination of captopril and diuretics: application in pharmaceutical dosage forms and human serum. J Chromatograph Separat Techniq. 2011;2(109):2.

33. Sultana N, Naveed S, Arayne MS. Development and validation of a simple and efficient RPLC method for analysis of captopril, metformin, pioglitazone and glibenclamide in API, formulations and human serum. Pharm Anal Acta. 2013;4(257):2.

34. Sultana N, Arayne MS, Naveed S. Simultaneous Determination of Captopril and Statins in API, Pharmaceutical Formulations and in Human Serum by RP-HPLC. Journal of the Chinese Chemical Society. 2010 Jun;57(3A):378-83.

35. Sultan N, Naveed S, Arayne MS. RP-HPLC Method for the simultaneous determination of captopril and H2-receptor antagonist: Application to interaction studies. Med chem. 2013;3(1):183-7.

36. Naveed S, Sultana N, Arayne MS, Akhtar M. In vivo interaction studies of captopril with flurbiprofen and ibuprofen on carrageenan induced inflammation. Open Access Sci Rep. 2013.

37. Naveed S. An overview of analytical determination of captopril in active pharmaceutical ingredients (API) formulation and biological fluids. J Bioequiv Availab. 2013;5:264-6.

38. Gupta VK, Chandra S, Lang H. A highly selective mercury electrode based on a diamine donor ligand. Talanta. 2005 Apr 30;66(3):575-80.

39. Gupta VK, Singh AK, Mehtab S, Gupta B. A cobalt (II)-selective PVC membrane based on a Schiff base complex of N, N′-bis (salicylidene)-3, 4-diaminotoluene. Analytica chimica acta. 2006 Apr 27;566(1):5-10.

40. Goyal RN, Gupta VK, Bachheti N. Fullerene-C60-modified electrode as a sensitive voltammetric sensor for detection of nandrolone—an anabolic steroid used in doping. Analytica chimica acta. 2007 Jul 30;597(1):82-9.

41. Gupta VK, Singh AK, Al Khayat M, Gupta B. Neutral carriers based polymeric membrane electrodes for selective determination of mercury (II). Analytica chimica acta. 2007 May 2;590(1):81-90.

42. Gupta VK, Al Khayat M, Singh AK, Pal MK. Nano level detection of Cd (II) using poly (vinyl chloride) based membranes of Schiff bases. Analytica Chimica Acta. 2009 Feb 16;634(1):36-43.

43. Gupta VK, Rastogi A. Biosorption of lead (II) from aqueous solutions by non-living algal biomass Oedogonium sp. and Nostoc sp.—a comparative

study. Colloids and Surfaces B: Biointerfaces. 2008 Jul 15;64(2):170-8.

44. Gupta VK, Rastogi A. Equilibrium and kinetic modelling of cadmium (II) biosorption by nonliving algal biomass Oedogonium sp. from aqueous phase. Journal of Hazardous Materials. 2008 May 1;153(1-2):759-66.